Europe
AstraZeneca and the University of Oxford published Phase II clinical trial results for their COVID-19 vaccine in The Lancet. The data shows the vaccine is safe and offers a similar immune response in all adults.
The U.S. FDA has lifted a clinical hold on Cellectis’ Phase I MELANI-01 trial evaluating multiple myeloma candidate UCARTCS1 just months after working with the French biopharmaceutical company to adjust its trial protocol to enhance patient safety.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Lead Pharma has entered into a collaboration and license agreement with Roche, hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases.
The United States continues to headline an annual list of influential science researchers, but that lead is dipping as other global scientists gain recognition from their peers for the work they are conducting.
The U.S. Food and Drug Administration has four distinct approaches to speeding the drug approval process. Several of today’s announcements had one or more of these designations.
In addition to coming sooner than expected, the results are even better than expected. The trial hit all primary efficacy endpoints.
Finerenone is an oral, non-steroidal selective mineralocorticoid receptor antagonist (MRA).
There are similarities between the two COVID-19 vaccine candidates, and a few differences. Here’s a look.
Late Friday, the regulatory agency rejected the medication of sutimlimab due to deficiencies from a pre-license inspection of a third-party manufacturing facility.
PRESS RELEASES